Literature DB >> 79809

A possible role for propranolol in the treatment of renal osteodystrophy.

J F Caro, A Besarab, J F Burke, J A Glennon.   

Abstract

The effect of propranolol upon parathyroid hormone (P.T.H) concentrations was investigated in patients undergoing chronic haemodialysis. 9 patients receiving propranolol for the treatment of hypertension or angina pectoris were compared with 25 similar patients not taking the drug. P.T.H. and alkaline phosphatase concentrations were lower in patients receiving propranolol and there was less radiological evidence of renal osteodystrophy in these patients. Prospective studies are needed to determine whether propranolol may be helpful as an adjunct to other therapy in reversing or preventing renal osteodystrophy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 79809     DOI: 10.1016/s0140-6736(78)91447-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.

Authors:  Piergiorgio Bolasco
Journal:  Clin Cases Miner Bone Metab       Date:  2009-09

2.  Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure.

Authors:  F U Eke; M H Winterborn
Journal:  Arch Dis Child       Date:  1983-10       Impact factor: 3.791

3.  Effects of oral propranolol on parathyroid hormone secretion in chronic renal failure.

Authors:  K Farrington; J Hamzeh; Z Varghese; J F Moorhead
Journal:  Br Med J       Date:  1980-11-15

4.  Effect of propranolol and metoprolol on parathyroid hormone and calcitonin secretions in uraemic patients.

Authors:  B Coevoet; C Desplan; J L Sebert; R Makdassi; M Andrejak; J D Gheerbrant; M Tolani; C Calmette; M S Moukhtar; A Fournier
Journal:  Br Med J       Date:  1980-06-07

Review 5.  Effects of antihypertensive drugs on endocrine function.

Authors:  E P Brass
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.